Initiation: Radiating potential
Actinium Pharmaceuticals is developing a portfolio of radio-labelled antibodies to treat various cancers. Its lead product, Iomab-B, is due to start a pivotal Phase III trial in H115 for use as a conditioning agent before hematopoietic stem cell therapy (HSCT, bone marrow transplantation) in elderly relapsed/refractory acute myeloid leukaemia (AML) patients. Its other clinical product, Actimab-A, is in a Phase I/II trial in newly diagnosed AML in the elderly; interim data from this trial are due in Q414. We value Actinium Pharmaceuticals at $429m, or $15.23 per share (undiluted).Actinium Pharmaceuticals is a clinical-stage, biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell therapies. The company's key targeted conditioning product candidate is Iomab-B, an Antibody Radiation-Conjugates (ARC) that is comprised of the anti-CD45 mAb known as apamistamab or BC8 and the radioisotope iodine-131. The company is applying its CD33 targeting ARC product candidate lintuzumab-Ac-225 to multiple hematologic indications as CD33 is an antigen that has been found to be expressed in a majority of patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and 25% to 35% of patients with Multiple Myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.